Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

43. Need an add-on to metformin? Consider this

Need an add-on to metformin? Consider this Need an add-on to metformin? Consider this Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Need an add-on to metformin? Consider this View/ Open Date 2017-01 Format Metadata Abstract Need an add-on to metformin? Consider this. Sulfonylureas have been the preferred add (...) -on therapy to metformin for T2DM, but a study finds that DPP-4s have lower risks of death, CV events, and hypoglycemia. Practice changer: Consider a dipeptidyl peptidase-4 inhibitor before a sulfonylurea for patients with type 2 diabetes mellitus who require therapy in addition to metformin. URI Part of Citation Journal of Family Practice, 66(01) 2017: 42-44. Collections hosted by hosted by

PURLS2017

44. Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms

Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms 28506478 2017 05 16 2017 05 16 1097-6809 2017 May 12 Journal of vascular surgery J. Vasc. Surg. Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms. S0741-5214(17)30922-9 10.1016/j.jvs.2017.01.070 Diabetes counteracts formation and rupture of abdominal aortic aneurysms, possibly through arterial matrix accumulation. Use of metformin, on the other hand, reduces arterial (...) accumulation of matrix molecules. Consequently, we hypothesized that metformin treatment may reverse the protective role of diabetes on the development and course of aneurysms, that is, that metformin would be associated with aneurysm rupture among individuals with diabetes. Using nationwide Danish registry data, we performed a nested case-control study on the association between long-term use of metformin and ruptured abdominal aortic aneurysm (RAAA). The source population was defined as all individuals

EvidenceUpdates2017

46. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT.

Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. 28331909 2017 03 23 2017 04 03 2476-4108 14 12 2016 Dec International journal of reproductive biomedicine (Yazd, Iran) Int J Reprod Biomed (Yazd) Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. 743-754 Insulin resistance and hyperinsulinemia may play (...) a role in pathogenesis of PCOS. One of the common therapeutic methods is using insulin-sensitizing drugs such as metformin and thiazolidinediones. The purpose was to determine the effect of metformin and pioglitazone on clinical, hormonal and metabolic parameters in women with PCOS. Eighty four women randomly received one of the following for 3 months: metformin (n=28) (500 mg three times a day), pioglitazone (30 mg daily) (n=28) and combination of both metformin and pioglitazone (n=28) (30 mg/day

International journal of reproductive biomedicine (Yazd, Iran)2017

47. Toxicokinetics of Metformin During Hemodialysis

Toxicokinetics of Metformin During Hemodialysis 29318220 2018 11 13 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Toxicokinetics of Metformin During Hemodialysis. 759-762 10.1016/j.ekir.2017.02.017 Ayoub Paul P Biochemistry Department, University of Montreal Health Center, University of Montreal, Montreal, Quebec, Canada. Hétu Pierre-Olivier PO Department of Nephrology, Verdun Hospital, University of Montreal, Montreal, Quebec, Canada. Cormier Monique M Department

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

48. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. 28225996 2017 02 22 2017 05 10 2359-4292 61 2 2017 Mar-Apr Archives of endocrinology and metabolism Arch Endocrinol Metab Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. 188-192 S2359-39972017000200188 10.1590/2359-3997000000242 To evaluate the effect of diacerein as an add-on to metformin in patients (...) with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all

Archives of endocrinology and metabolism2017

49. Which patients with metabolic syndrome benefit from metformin?

Which patients with metabolic syndrome benefit from metformin? Which patients with metabolic syndrome benefit from metformin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Which patients with metabolic syndrome benefit from metformin? View/ Open Date 2016-11 Format Metadata Abstract Q Which patients with metabolic (...) syndrome benefit from metformin? Evidence-based answer: Patients at highest risk for progression to diabetes benefit from metformin. In patients with metabolic syndrome who are in the highest-risk quartile for progression to diabetes (predicted mean 3-year risk, 60%), metformin, 850 mg twice daily, reduces the absolute risk by about 20% over a 3-year period. Metformin doesn't reduce the incidence in patients at lower risk of progression (strength of recommendation [SOR]: C, post-hoc analysis

Clinical Inquiries2017

50. [Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V]

[Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a (...) Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag

Health Technology Assessment (HTA) Database.2017

51. [Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V]

[Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V] Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung; Auftrag A16-4 [Saxagliptin / metformin - benefit assessment according to § 35a Social Code Book V] Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung; Auftrag A16-4 [Saxagliptin / metformin - benefit assessment according (...) to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Health Technology Assessment (HTA) Database.2017

53. Metformin Use in Patients With Historical Contraindications

Metformin Use in Patients With Historical Contraindications 28055052 2017 12 08 2018 12 02 1539-3704 166 3 2017 02 07 Annals of internal medicine Ann. Intern. Med. Metformin Use in Patients With Historical Contraindications. 225-226 10.7326/M16-2712 Lipska Kasia J KJ From Yale School of Medicine, New Haven, Connecticut. eng K23 AG048359 AG NIA NIH HHS United States L30 AG045923 AG NIA NIH HHS United States P30 AG021342 AG NIA NIH HHS United States Journal Article Research Support, N.I.H (...) ., Extramural Comment 2017 01 03 United States Ann Intern Med 0372351 0003-4819 0 Hypoglycemic Agents 9100L32L2N Metformin AIM IM Ann Intern Med. 2017 Feb 7;166(3):191-200 28055049 Contraindications Diabetes Mellitus, Type 2 Humans Hypoglycemic Agents Metformin 2017 1 6 6 0 2017 12 9 6 0 2017 1 6 6 0 ppublish 28055052 2595890 10.7326/M16-2712 PMC5334793 NIHMS850043 N Engl J Med. 1998 Jan 22;338(4):265-6 9441244 Ann Intern Med. 2011 May 3;154(9):602-13 21403054 Lancet. 1998 Sep 12;352(9131):854-65 9742977

Annals of Internal Medicine2017 Full Text: Link to full Text with Trip Pro

55. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.

Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving (...) of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017 Sep;108(3):426-41. [80 references] This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria. Age Group UMLS Concepts ICD9CM (628.9), (256.4) MSH

National Guideline Clearinghouse (partial archive)2017

59. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells 28721276 2018 11 13 2056-3973 2 2016 NPJ aging and mechanisms of disease NPJ Aging Mech Dis Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells. 16026 10.1038/npjamd.2016.26 Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children (...) . This syndrome is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48 h treatment with 5 mmol/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived

NPJ aging and mechanisms of disease2016 Full Text: Link to full Text with Trip Pro

60. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions Management Briefs Search the HSR&D website Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Brief no. 116 » Issue 116 October 2016 The systematic review reported on here is a product of the VA/HSR&D Quality Enhancement Research Initiative (QUERI) Evidence-Based Synthesis Program (...) . Metformin Use in Patients with Historical Contraindications or Precautions Metformin is an oral hypoglycemic medication used primarily for treating type 2 diabetes mellitus. Evidence suggests that in addition to improving glycemic control, metformin may be associated with improved all-cause and cardiovascular mortality and decreased risk of some cancers. However, clinicians have traditionally been advised by the U.S. Food and Drug Administration (FDA) to exercise caution in prescribing metformin

Veterans Affairs - R&D2016